Heart failure is recognized as a complex clinical syndrome because it involves endocrine, molecular, and neurohormonal axes. Although the activation of renin-angiotensin system and sympathetic system plays a major role in the pathogenesis of heart failure, there is growing recent evidence to suggest involvement of immune system in its development and progression.
Early reports suggesting elevation of serum tumor necrosis factor (TNF) level in heart failure patients started coming more than 2 decades ago. 1 Since then, multiple cytokines were noted to be elevated in patients with heart failure like interleukin-1 (IL-1), IL-6, and IL-10. [2] [3] [4] Whether activation of immune system is a cause or consequence to myocyte injury is still controversial. Measurement of cell-mediated immunity is frequently used in the posttransplant patients receiving immunosuppressants as a measure of immune response. 5 The aim of our study is to evaluate the role of immune function testing in patients with pretransplant stage D heart failure.
Methods
This study was approved by the Cleveland Clinic Institutional Review Board. No extramural funding was used to support this work. We evaluated cell-mediated immune function in a large database of more than 500 consecutive patients with advanced end-stage heart failure referred for cardiac transplant evaluation and other advanced heart failure therapies to a tertiary level reference center between 2007 and 2010. Of these, 368 patients had performed testing of cell-mediated immune function to assess the underlying immune status prior to immunosuppressive therapy. Patients underwent comprehensive evaluation either in the hospital or in our advanced heart failure clinic, including laboratory investigations, echocardiogram, metabolic stress test, and cardiac catheterization. We reviewed electronic medical records to collect baseline characteristics, which included demographic information, baseline clinical characteristics, medical history, history of infection and immunodeficient states, medications (including active antibiotics use at the time of testing), laboratory test results, and procedures performed including echocardiographic data. Participation in this retrospective study did not require any alteration to the medical management of patients, and the database was managed by independent researchers not responsible for care of these patients.
We use a cell-mediated immune function assay (Immuknow; Cylex Inc, Columbia, MD) to estimate the degree of cell-mediated immunity. Briefly, patient's whole blood is incubated for 15-18 hours with and without the stimulant phytohemagglutinin. Phytohemagglutinin increases adenosine triphosphate (ATP) synthesis within the cells. Magnetic beads coated with anti-CD4 monoclonal antibodies are added to both samples. Then the samples are washed over a strong magnet, and a lysis reagent is added. This releases intracellular ATP which is measured using a luminometer. Luciferin, a luminescence reagent, is used for this step. The results of the immune function assay were reported in nanograms per milliliter of ATP. Based on previous studies and laboratory data, immune response was categorized into 3 groups [5] [6] [7] : low or poor immune response (≤225 ng/mL), moderate or normal immune response (226-524 ng/mL), and strong immune response (≥525 ng/mL). The primary outcome of interest was the composite of all-cause mortality or cardiac transplantation. We used medical records and the hospital transplantation index to identify both patients and date of cardiac transplantation. Because infection or other mediators of immune response can affect posttransplant outcomes, the cases were censored upon the occurrence of transplant as reaching the primary end point.
Dichotomous categorical data were reported as percentages, and the χ 2 test was used to detect differences. Continuous variables were described as mean and SD; comparisons between 2 groups were done with the t test or Wilcoxon rank sum text. Because we were expecting non-normal distribution for some continuous variables across the 3 immune response groups due to their small sample sizes, description of these continuous outcomes was with median and interquartile range (IQR); comparisons among the 3 groups were done with the Kruskal-Wallis test. Time to event analysis was performed using Kaplan-Meier method, and differences between curves were calculated using the log-rank test. Univariate analyses for association between immune function groups, important clinical and laboratory variables, and the primary outcome were performed using Cox proportional hazards models. Variables with a P b .2 were included for multivariate Cox models. The associations were provided as hazard ratios (HRs) and their 95% CIs. Differences with P b .05 were considered statistically significant in multivariate analyses. We also performed univariate and multivariate logistic regression analysis to evaluate the association between clinical and laboratory variables and poor immune function (b225 ng/mL). The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents. All statistics were performed using SPSS version 20.0 (IBM, Armonk NY) and R 2.15.1 (www.r-project.org).
Results
Among 500 consecutive subjects in the database, 368 subjects were included for analysis with cell-mediated immune function assay performed. None of the subjects experienced active infection or received antibiotics at the time of testing by medical record review. In this study cohort, 258 patients (70.1%) had normal immunity, whereas 41 patients (11.1%) had poor immunity and 69 patients (18.7%) had strong immunity. The distribution of the cell-mediated immune function measurement is illustrated in Figure 1 , and baseline characteristics of all the 3 groups are illustrated in Table I .
The primary outcome occurred in 63.4%, 45.3%, and 34.8% in the poor immunity, normal immunity, and strong immunity group, respectively. Patients with strong immunity had better survival when compared with the other 2 groups, and patients with poor immunity had the worst chance of survival in Kaplan-Meier analysis (log-rank test P = .012) (Figure 2) . In univariate analysis, immune function was strongly associated with the primary outcome of all-cause mortality or cardiac transplantation (P = .014). In comparison to the normal immune group, the poor immune function seems to increase the risk of the primary outcome (HR 1.53, 95% CI 1.00-2.34); the strong immune function seems to protect against the occurrence of the primary outcome (HR 0.67, CI 0.43-1.04) (Table II) . Other variables which had some association with the primary outcome (P b .2) were race, New York Heart Association class, diabetes, use of β-blockers and angiotensin-converting enzyme (ACE) inhibitors, serum sodium, blood urea nitrogen, albumin, bilirubin, B-type natriuretic peptide, and hemoglobin. When all these variables were included in multivariate analysis, immune function test lost its overall significance to predict primary outcome (P = .11). Although the effect estimate was larger for the poor immune function group, the direction to an increased risk of the primary outcome was maintained (HR 2.18, 95% CI 1.01-4.71). In contrast, the borderline protective effect of the strong immune function disappeared in multivariate analyses (HR 0.84, 95% CI 0.39-1.78) (Table II) .
We also looked for associations between patient variables and immune function. Comparing between the 3 groups, patients with the weakest cell-mediated immune function had higher B-type natriuretic peptide and blood urea nitrogen levels (Table I) . In univariate and multivariate analyses, none of the patient variables had significant association with immune function when analyzed as continuous variable. But when variables with P b .2 were included for multivariate analysis, only history of ventricular tachycardia reached borderline significance (odds ratio 0.35, 95% CI 0.13-0.96, P = .04).
Discussion
In patients with advanced, "stage D" heart failure, we observed that stronger cell-mediated immunity was associated with better survival free of transplantation. However, stronger cell-mediated immune function was not associated with lower all-cause mortality or cardiac transplantation when adjusted for other clinical variables. In addition, we did not find any significant association between immune function and individual patient variables. Taken together, diminished cell-mediated immunity tracks with disease progression in advanced heart failure but did not provide independent prognostic value.
The immune system plays an important but complex role in the pathogenesis of heart failure. Overall levels of multiple cytokines have been elevated in patients with heart failure, but in most cases, they are highly variable and may not provide the best discrimination in patients with versus without adverse consequences for reliable clinical use. The most studied cytokine is TNFα. The circulating level of this cytokine was increased in patients with cachexia.
1 Subsequently TNF-α was labeled as a major pathogenic mediator of heart failure progression. However, even after extensive investigations, the role of modulating immune system in heart failure remains elusive. The largest of such anti-TNFα trial was the RENEWAL trial. 8 However, this trial was terminated prematurely because etanercept did not have any clinically significant benefit on either death or heart failure hospitalization. Multiple hypotheses had been used to explain this phenomenon. Possible cardioprotective effect of TNFα was one of them. 9 Studies involving another anti-TNF inhibitor, thalidomide, again showed contradictory results. 10, 11 Monitoring of cell-mediated immune function has been used in the posttransplant setting in patients on immunosuppression. Poor cell-mediated immune function measured by this clinically available assay was associated with increased infection risk in 296 heart transplant patients when the predictive ability to detect rejections was inconclusive. 12 Cell-mediated immune function assay was helpful in assessing the overall immune function in lung transplant patients, but it was not a reliable predictor of rejections or infections, as the test had poor performance characteristics in receiver operating characteristic curve analysis. 13 Similarly, in 83 pediatric heart transplant patients, cell-mediated immune function assay was not predictive of infections or rejections and hence was not recommended for routine monitoring of such patients.
14 In 504 solid organ transplant patients, a higher risk of rejection was associated with stronger immune response whereas higher risk of infection was with weaker immune response. 7 Another meta-analysis showed a high specificity but low sensitivity in identifying patients at risk of rejection. Summary receiver operating characteristic curve showed an area under the curve of 0.51 for rejection, confirming poor overall accuracy. Similarly, this analysis produced inconsistent results in identifying patients at risk of infection, as well as low sensitivity and low specificity. 15 Recent studies evaluating the use of cell-mediated immune function assay in nontransplant patient population like those with inflammatory bowel disease and rheumatoid arthritis are emerging. 16, 17 Although the immune assay did not show any correlation with disease activity, it was helpful in identifying patients at increased risk of infection in these studies. Specifically, the immune assay level was significantly lower in patients with infection when compared with patients without.
To our knowledge, there are no studies looking into the role of immune function assay in advanced, "stage D" heart failure patients. Our initial hypothesis before this study, based on the available literature, was that the patients with higher activity of cytokines (and hence better immune function) are likely to have poorer prognosis. In contrast, the main finding that patients with stronger cell-mediated immune function portend better prognosis in univariate analysis and in KaplanMeier analysis, the significance of which was lost in multivariate analysis, suggesting that disease severity may play a contributing role to these findings. We also noted that the poor immune function group was at increased risk of primary outcome compared with the group with normal immunity. This effect was attenuated after adjusting for other variables in multivariable analysis, but the direction was maintained. Although limited by a retrospective medical record review, we have carefully considered concomitant factors that may have influenced the outcome of interest secondary to ongoing infections or other immunodeficiency states, issues that were unlikely encountered in this setting because these would be obvious contraindications for cardiac transplantation. It is conceivable that as patients progressed to more advanced stage of heart failure, their end-organ perfusion toward hematologic, hepatic, and immune systems maybe more markedly altered. Hence, these adverse functional and long-term consequences that were detectable by a cell-mediated immunity function assay likely represent underlying disease severity. Naturally, immunosuppressive therapy may have a difficult time balancing potential risks and benefits if underlying immune dysfunction is underappreciated. 8, [18] [19] [20] Indeed, our findings are also consistent with prior research on the prognostic role of lymphopenia in advanced heart failure, 21 which is one variable used in the Seattle Heart Failure Model for risk stratification. 
Figure 2
Kaplan-Meier curves showing better survival of patients with stronger immune function compared with those with normal and poor immune function (log-rank test P = .012).
This is primarily a hypothesis-generating study but sheds some light on the complex interaction between immune system and heart failure. It may be reasonable to obtain pretransplant immune function testing because it may provide some prognostic information, although there is no clear way to modify this risk at the present time. This may help to tailor the posttransplant immunosuppressive therapy. If further studies show a similar relationship, it may be time to think about novel therapies to enhance immunity. Nevertheless, our hypothesisgenerating study has several limitations. Our study is a retrospective study and was not designed primarily to evaluate the role of cell-mediated immunity in heart failure. We did not measure any cytokine level in any patients, nor do we have any information regarding infections and other coexisting immunodeficiencies, although these patients are often excluded as being transplant ineligible. In a population with no immunosuppressive therapy, the proportion of individuals with poor immune function was relatively low (11%), and we only performed a 1-time measurement as part of pretransplant evaluation. Nevertheless, these findings provide insights into the need to better understand how the immune system may affect different individuals with advanced heart failure, rather than a one-size-fits-all approach to immune modulation. ⁎ Adjusted for race, New York Heart Association class, diabetes, chronic kidney disease, β-blocker, ACE inhibitor, sodium, blood urea nitrogen, albumin, bilirubin, troponin, hemoglobin, and BNP.
